Literature DB >> 15324516

Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.

Andrew J Palmer1, Stéphane Roze, William J Valentine, Michael E Minshall, Clarice Hayes, Alan Oglesby, Giatgen A Spinas.   

Abstract

OBJECTIVES: Various factors influence the risk of complications in type 2 diabetes patients. The isolated impact of single risk factors on long-term outcomes is unclear. The aim of this study was to calculate the projected effects on life expectancy (LE), quality-adjusted LE (QALE) and total costs of complications (TC) of 10% improvements in baseline levels of either total cholesterol (T-CHOL), high-density lipoprotein cholesterol (HDL), systolic blood pressure (SBP), glycosylated haemoglobin (HbA1c), and all four parameters combined.
METHODS: A cohort of newly diagnosed patients (baseline age 52 years, HbA1c 9.1%, SBP 137 mmHg, T-CHOL 212 mg/dL, and HDL 39 mg/dL) was defined. The CORE Diabetes Model was used to simulate LE, QALE and TC (US third-party payer perspective discounted at 3% annually) over patients' lifetimes, assuming no change in risk factors, an isolated 10% improvement in each parameter, or a 10% improvement in all parameters simultaneously.
RESULTS: Improved HbA1c led to increases in LE and QALE of 1.00 and 0.81 years respectively, and decreased TC of (US) 10,800 dollars/patient. Improved SBP led to improvements in LE and QALE of 0.67 and 0.55 years respectively and decreased TC of 7,049 dollars. Decreased T-CHOL led to improvements in LE and QALE of 0.29 and 0.20 years, respectively, and increased TC of 1,923 dollars. Increased HDL led to improvements in LE and QALE of 0.28 and 0.18 years respectively, and increased TC of 2,162 dollars. Simultaneous improvements in all parameters led to projected improvements in LE and QALE of 2.17 and 1.72 years respectively, and decreased TC of 14,533 dollars.
CONCLUSIONS: Combined improvements in HbA1c, lipid levels and SBP produced the greatest benefits in terms of LE, QALE and TC. A 10% improvement in HbA1c had the greatest impact on these three outcomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324516     DOI: 10.1185/030079903125002611

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  10 in total

1.  The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.

Authors:  Elbert S Huang; Morgan Shook; Lei Jin; Marshall H Chin; David O Meltzer
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

2.  Making Inroads in Addressing Population Health in Underserved Communities With Type 2 Diabetes.

Authors:  Luigi F Meneghini; Addie L Fortmann; Taylor L Clark; Kellie Rodriguez
Journal:  Diabetes Spectr       Date:  2019-11

3.  Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.

Authors:  Carol H Wysham; Patrick Lefebvre; Dominic Pilon; Mike Ingham; Marie-Hélène Lafeuille; Bruno Emond; Rhiannon Kamstra; Wing Chow; Michael Pfeifer; Mei Sheng Duh
Journal:  BMC Endocr Disord       Date:  2017-06-08       Impact factor: 2.763

Review 4.  How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review.

Authors:  Xinyang Hua; Thomas Wai-Chun Lung; Andrew Palmer; Lei Si; William H Herman; Philip Clarke
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

5.  Efficacy of Pharmacist Based Diabetes Educational Interventions on Clinical Outcomes of Adults With Type 2 Diabetes Mellitus: A Network Meta-Analysis.

Authors:  Allah Bukhsh; Tahir M Khan; Shaun W H Lee; Learn-Han Lee; Kok-Gan Chan; Bey-Hing Goh
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

6.  Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences.

Authors:  Vivian A Fonseca; Hayden Smith; Nitesh Kuhadiya; Sharice M Leger; C Lillian Yau; Kristi Reynolds; Lizheng Shi; Roberta H McDuffie; Tina Thethi; Jennifer John-Kalarickal
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

7.  Medical assistant health coaching ("MAC") for type 2 diabetes in diverse primary care settings: A pragmatic, cluster-randomized controlled trial protocol.

Authors:  Addie L Fortmann; Athena Philis-Tsimikas; Johanna A Euyoque; Taylor L Clark; Daniela G Vital; Haley Sandoval; Julia I Bravin; Kimberly L Savin; Jennifer A Jones; Scott Roesch; Todd Gilmer; Thomas Bodenheimer; James Schultz; Linda C Gallo
Journal:  Contemp Clin Trials       Date:  2020-10-11       Impact factor: 2.226

8.  Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO).

Authors:  Hui Shao; Vivian Fonseca; Charles Stoecker; Shuqian Liu; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.558

9.  Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.

Authors:  Sean D Sullivan; Rafael Alfonso-Cristancho; Chris Conner; Mette Hammer; Lawrence Blonde
Journal:  Cardiovasc Diabetol       Date:  2009-02-26       Impact factor: 9.951

10.  Comparative effectiveness of telemedicine strategies on type 2 diabetes management: A systematic review and network meta-analysis.

Authors:  Shaun Wen Huey Lee; Carina Ka Yee Chan; Siew Siang Chua; Nathorn Chaiyakunapruk
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.